lumacaftor and Polycystic-Kidney--Autosomal-Dominant

lumacaftor has been researched along with Polycystic-Kidney--Autosomal-Dominant* in 2 studies

Other Studies

2 other study(ies) available for lumacaftor and Polycystic-Kidney--Autosomal-Dominant

ArticleYear
VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:11

    Topics: Aminopyridines; Animals; Benzodioxoles; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Female; Kidney; Male; Mice; Mice, Inbred C57BL; Polycystic Kidney, Autosomal Dominant

2021
A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
    The Journal of biological chemistry, 2018, 07-20, Volume: 293, Issue:29

    Autosomal dominant polycystic kidney disease (ADPKD) is associated with progressive enlargement of cysts, leading to a decline in function and renal failure that cannot be prevented by current treatments. Mutations in

    Topics: Aminopyridines; Animals; Benzodioxoles; Calcium; Cell Line; Cell Proliferation; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Heat-Shock Proteins; Kidney; Mice; Mice, Inbred C57BL; Polycystic Kidney, Autosomal Dominant; Transcription Factor CHOP

2018